Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Diabetologie
Erschienen in: Die Diabetologie 4/2021

17.05.2021 | Typ-2-Diabetes | DDG Praxisempfehlungen

Therapie des Typ-2-Diabetes

verfasst von: Prof. Dr. med. Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Hans-Martin Reuter, Erhard Siegel

Erschienen in: Die Diabetologie | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://​www.​deutsche-diabetes-gesellschaft.​de/​behandlung/​leitlinien) befinden sich alle PDF zum kostenlosen Download. …
Literatur
1.
2.
Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome. Circulation 120:1640–1645PubMed
3.
4.
Heinemann L, Kaiser P, Freckmann G et al (2018) HbA1c-Messung in Deutschland: Ist die Qualität ausreichend für Verlaufskontrolle und Diagnose? Diabetologie 13:46–53
5.
Landgraf R, Nauck M, Freckmann G et al (2018) Fallstricke bei der Diabetesdiagnostik: Wird zu lax mit Laborwerten umgegangen? Dtsch Med Wochenschr 143:1549–1555PubMed
6.
Nauck M, Gerdes C, Petersmann A et al (2020) Definition, Klassifikation und Diagnostik des Diabetes mellitus. Update 2020. Diabetologie 15(Suppl. 01):S9–S17
7.
Zhang Y, Pan XF, Chen J et al (2020) Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Diabetologia 63:21–33PubMed
8.
9.
Wang R, Song Y, Yan Y et al (2016) Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: a meta-analysis. Atherosclerosis 254:193–199PubMed
10.
Parhofer KG, Birkenfeld AL, Krone W et al (2020) Lipidtherapie bei Patienten mit Diabetes mellitus. Diabetologie 15(Suppl. 01):S160–S165
11.
The Task Force for the management of arterial hypertension of the European Society of cardiology (ESC), European Society of Hypertension (ESH) (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104
12.
Forouhi NG, Misra A, Mohan V et al (2018) Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ 361:k2234PubMedPubMedCentral
13.
Serra-Majem L, Román-Viñas B, Sanchez-Villegas A et al (2019) Benefits of the Mediterranean diet: epidemiological and molecular aspects. Mol Aspects Med 67:1–55PubMed
14.
Taylor R, Al-Mrabeh A, Sattar N (2019) Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol
15.
Evert AB, Dennison M, Gardner CD et al (2019) Nutrition therapy for adults with Diabetes or prediabetes: a consensus report. Diabetes Care 42(05):731–754PubMedPubMedCentral
16.
Chester B, Babu JR, Greene MW et al (2019) The effects of popular diets on type 2 diabetes management. Diabetes Metab Res Rev 35:e3188PubMed
17.
Kempf K, Altpeter B, Berger J et al (2017) Efficacy of the telemedical lifestyle intervention program TeLiPro in advanced stages of type 2 diabetes: a randomized controlled trial. Diabetes Care 40(07):863–871PubMed
18.
Lean MEJ, Leslie WS, Barnes AC et al (2019) Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2‑year results of the DiRECT open-label, cluster-randomized trial. Lancet Diabetes Endocrinol 7:344–355PubMed
19.
Adipositas – Prävention und Therapie. AWMF Register Nr. 050-001.
20.
Lawall H, Huppert P, Rümenapf G et al (2015) Periphere arterielle Verschlusskrankheit (PAVK), Diagnostik, Therapie und Nachsorge. AWMF Register Nr. 065-003
21.
22.
23.
24.
Roeb E, Steffen HM, Bantel H et al (2015) S2k-Leitlinie: Nicht-alkoholische Fettlebererkrankungen. AWMF Register Nr. 021-025
25.
26.
27.
28.
Piercy KL, Richard P, Troiano RP et al (2018) The physical activity guidelines for Americans. JAMA 320(19):2020–2028PubMed
29.
Jabardo-Camprubí G, Donat-Roca R, Sitjà-Rabert M et al (2020) Drop-out ratio between moderate to high-intensity physical exercise treatment by patients with, or at risk of, type 2 diabetes mellitus: a systematic review and meta-analysis. Physiol Behav 215:112786PubMed
30.
The Look AHEAD Research Group (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145–154PubMedCentral
31.
Unick JL, Gaussoin SA, Hill JO et al (2017) Objectively assessed physical activity and weight loss maintenance among individuals enrolled in a lifestyle intervention. Obesity 25(11):1903–1909PubMed
32.
The Look AHEAD Research Group (2016) Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol 4:913–921
33.
Gregg EW, Lin J, Bardenheier B et al (2018) Impact of intensive lifestyle intervention on disability-free life expectancy: the look AHEAD study. Diabetes Care 41:1040–1048PubMedPubMedCentral
34.
Look AHEAD Research Group, Chao AM, Wadden TA, Berkowitz RI et al (2020) Weight change 2 years after termination of the intensive lifestyle intervention in the Look AHEAD Study. Obesity 28:893–890
35.
Yang D, Yang Y, Li Y et al (2019) Physical exercise as therapy for type 2 diabetes mellitus: from mechanism to orientation. Ann Nutr Metab 74((04):313–321PubMed
36.
Tarp J, Støle AP, Blond K et al (2019) Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and metaanalysis. Diabetologia 62:1129–1142PubMedPubMedCentral
37.
Liu Y, Ye W, Chen Q et al (2019) Resistance exercise intensity is correlated with attenuation of HbA1c and insulin in patients with type 2 diabetes: a systematic review and meta-analysis. Int J Environ Res Public Health 16(01):E140PubMed
38.
Pan A, Yeli Wang Y, Talaei M et al (2015) Relation of active, passive, and quitting smoking with incident diabetes: a meta-analysis and systematic review. Lancet Diabetes Endocrinol 3(12):958–996PubMedPubMedCentral
39.
Kar D, Gillies C, Nath M et al (2019) Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 56:839–850PubMedPubMedCentral
40.
41.
Lazarus B, Wu A, Shin JI et al (2018) Association of metformin use with risk of lactic acidosis across the range of kidney function. A community-based cohort study. JAMA Intern Med 178(07):903–910PubMedPubMedCentral
42.
Griffin SJ, Leaver JK, Irving GJ et al (2017) Impact of metformin on cardiovascular disease: a meta-analysis of randomized trails among people with type 2 diabetes. Diabetologia 60:1620–1629PubMedPubMedCentral
43.
Palmer SC, Mavridis D, Nicolucci A et al (2016) Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA 316(03):313–324PubMed
44.
45.
Mallik R, Chowdhury TA (2018) Metformin in cancer. Diabetes Res Clin Pract 143:409–419PubMed
46.
Thakur S, Daley B, Klubo-Gwiezdzinska J (2019) The role of the antidiabetic drug metformin in the treatment of endocrine tumors. J Mol Endocrinol
47.
De A, Kuppusamy G (2019) Metformin in breast cancer: preclinical and clinical evidence. Curr Probl Cancer
48.
49.
50.
Aljofan M, Riethmacher D (2019) Anticancer activity of metformin: a systematic review of the literature. Future Sci OA 5(08):FSO410PubMedPubMedCentral
51.
Feng Z, Zhou X, Liu N et al (2019) Metformin use and prostate cancer risk: a meta-analysis of cohort studies. Medicine 98(12):e14955PubMedPubMedCentral
52.
Oshima M, Jun M, Ohkuma T et al (2019) The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. Diabetologia 62:1988–1997PubMedPubMedCentral
53.
The ADVANCE Collaborative Group. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
54.
CAROLINA Investigators, Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA randomized clinical trial. JAMA 322(12):1155–1166
55.
Rados DV, Pinto LC, Remonti LR et al (2016) The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 13(06):e1002091PubMedPubMedCentral
56.
Azoulay L, Suissa S (2017) Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care 40:706–714PubMed
57.
Bain S, Druyts E, Balijepalli C et al (2017) Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data. Diabetes Obes Metab 19(03):329–335PubMed
58.
Zhuang XD, He X, Yang DY et al (2018) Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166371 participants from170 randomized controlled trials. Cardiovasc Diabetol 17(01):79PubMedPubMedCentral
59.
Powell WR, Christiansen CL, Miller DR (2018) Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments. Diabetes Ther 9(04):1431–1440PubMedPubMedCentral
60.
Simpson SH, Lee J, Choi S et al (2015) Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 3(01):43–5134PubMed
61.
62.
Hemmingsen B, Schroll JB, Jorn Wetterslev J et al (2014) Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2(03):E162–E175PubMedPubMedCentral
63.
Vaccaro O, Masulli M, Nicolucci M et al (2017) Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomized, multicenter trial. Lancet Diabetes Endocrinol 5:887–897PubMed
64.
Chen K, Kang D, Yu M et al (2018) Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase‑4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: a meta-analysis of long-term randomized controlled trials. Diabetes Obes Metab 20:1029–1033PubMed
65.
Patorno E, Schneeweiss S, Gopalakrishnan C et al (2019) Using real-world data to predict findings of an ongoing phase IV cardiovascular outcome trial: Cardiovascular safety of linagliptin versus glimepiride. Diabetes Care 42:2204–2210PubMedPubMedCentral
66.
Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–1326PubMed
67.
White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327–1335PubMed
68.
TECOS Study Group, Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373(03):232–242
69.
Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovasculareEvents in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA Randomized Clinical Trial. JAMA 321(01):69–79PubMed
70.
Monami M, Ahrén B, Dicembrini I et al (2013) Dipeptidyl peptidase‑4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15:112–120PubMed
71.
Xu S, Zhang X, Tang L et al (2017) Cardiovascular effects of dipeptidylpeptidase‑4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review. Postgrad Med 129:205–215PubMed
72.
Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA 319(15):1580–1591PubMedPubMedCentral
73.
Ling J, Cheng P, Ge L et al (2019) The efficacy and safety of dipeptidyl peptidase‑4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetol 56:249–272PubMed
74.
Li L, Li S, Deng K et al (2016) Dipeptidyl peptidase‑4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMJ 352:i610PubMedPubMedCentral
75.
Guo WQ, Li L, Su Q et al (2017) Effect of dipeptidylpeptidase‑4 inhibitors on heart failure: a network meta-analysis. Value Health 20:1427–1430PubMed
76.
Nauck MA, Meier JJ, Cavender MA et al (2017) Cardiovascular actions and clinical outcomes with glucagon-like peptide‑1 receptor agonists and dipeptidyl peptidase‑4 inhibitors. Circulation 136(09):849–870PubMed
77.
Sinha B, Ghosal S (2019) Meta-analyses of the effects of DPP‑4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 150:8–16PubMed
78.
Tkáč I, Raz I (2017) Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 40:284–286PubMed
79.
Pinto LC, Rados DV, Barkann SS et al (2018) Dipeptidyl peptidase‑4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep 8(01):782PubMedPubMedCentral
80.
Overbeek JA, Bakker M, van der Heijden AAWA et al (2018) Risk of dipeptidyl peptidase‑4 (DPP-4) inhibitors on site specific cancer: a systematic review and meta-analysis. Diabetes Metab Res Rev 34:e3004PubMed
81.
Abrahami D, Douros A, Yin H et al (2018) Dipeptidyl peptidase‑4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 360:k872PubMedPubMedCentral
82.
Li G, Crowley MJ, Tang H et al (2019) Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 42(07):e119–e121PubMedPubMedCentral
83.
Storgaard H, Gluud LL, Bennett C et al (2016) Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE 11(11):e166125PubMedPubMedCentral
84.
Monami M, Liistro F, Scatena A et al (2018) Short and medium-term efficacy of sodium glucose co-transporter‑2 (SGLT-2) inhibitors: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 20(05):1213–1222PubMed
85.
Usman MS, Siddiqi TJ, Memon MM et al (2018) Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol 25(05):495–502PubMed
86.
Mishriky BM, Tanenberg RJ, Sewell KA et al (2018) Comparing SGLT‑2 inhibitors to DPP‑4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 44(02):112–120PubMed
87.
Seidu S, Kunutsor SK, Cos X et al (2018) SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes 12(03):265–283PubMed
88.
Rådholm K, Wu JH, Wong MG et al (2018) Effects of sodium-glucose cotransporter‑2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes—a systematic review. Diabetes Res Clin Pract 140:118–128PubMed
89.
Sinha B, Ghosal S (2019) Meta-analyses of the effects of DPP‑4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 150:8–16PubMed
90.
Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 319(15):1580–1591PubMedPubMedCentral
91.
Aronson R, Frias J, Goldman A et al (2018) Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab 20:1453–1460PubMedPubMedCentral
92.
Hollander P, Hill J, Johnson J et al (2019) Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on Metformin. Curr Med Res Opin 35(08):1335–1343PubMed
93.
Puckrin R, Saltiel MP, Reynier P et al (2018) SGLT‑2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55(05):503–514PubMed
94.
95.
Dave CV, Schneeweiss S, Patorno E (2019) Comparative risk of genital infections associated with sodium glucose co-transporter‑2 inhibitors. Diabetes Obes Metab 21:434–438PubMed
96.
Lega IC, Bronskill SE, Campitelli MA et al (2019) Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes Metab 21:2394–2404PubMed
97.
McGovern AP, Hogg M, Shields BM et al (2020) Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diab Res Care 8:e1238PubMedPubMedCentral
98.
Yang JY, Wang T, Pate V et al (2020) Real-world evidence on sodium-glucose cotransporter‑2 inhibitor use and risk of Fournier’s gangrene. BMJ Open Diab Res Care 8:e985PubMedPubMedCentral
99.
Silverii GA, Dicembrini I, Monami M et al (2020) Fournier’s gangrene and sodium-glucose co-transporter‑2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 22:272–275PubMed
100.
101.
CANVAS Program Collaborative Group, Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657
102.
Scheen AJ (2018) Does lower limb amputation concern all SGLT2 inhibitors? Nat Rev Endocrinol 14(06):326–328PubMed
103.
104.
Inzucchi SE, Iliev H, Pfarr E et al (2018) Empagliflozin and assessment of lower limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41:e4–e5PubMed
105.
Zhou Z, Jardine M, Perkovic V et al (2019) Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia 62(10):1854–1867PubMedPubMedCentral
106.
Perkovic V, Jardine MJ, Neal N et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306PubMed
107.
Mahaffey KW, Jardine MJ, Bompoint S et al (2019) Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 140:739–750PubMedPubMedCentral
108.
Kohler S, Kaspers S, Salsali A et al (2018) Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride. Diabetes Care 41(08):1809–1816PubMed
109.
110.
Tang HL, Li DD, Zhang JJ et al (2016) Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 18(12):1199–1206PubMed
111.
Li X, Li T, Cheng Y et al (2019) Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis. Diabetes Metab Res Rev 35:e3170PubMed
112.
Hidayat K, Du X, Shi BM (2019) Risk of fracture with dipeptidyl peptidase‑4 inhibitors, glucagon-like peptide‑1 receptor agonists, or sodium-glucose cotransporter‑2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporos Int 30:1923–1940PubMed
113.
Fralick M, Schneeweiss S, Patorno E (2017) Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 376:2300–2303PubMed
114.
Monami M, Nreu B, Zannoni S et al (2017) Effects of SGLT2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials. Diabetes Res Clin Pract 130:53–60PubMed
115.
Fadini GP, Bonora BM, Avogaro A (2017) SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 60:1385–1389PubMed
116.
Thiruvenkatarajan V, Meyer EJ, Nanjappa N et al (2019) Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter‑2 inhibitors: a systematic review. Br J Anaesth 123(01):27–36PubMed
117.
Milder DA, Milder TY, Kam PCA (2018) Sodium-glucose co-transporter type‑2 inhibitors: pharmacology and perioperative considerations. Anaesthesia 73:1008–1018PubMed
118.
Donnan K, Segar L (2019) SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol 846:23–29PubMedPubMedCentral
119.
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128PubMed
120.
Wanner C, Inzucchi SE, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334PubMed
121.
Cherney DZI, Zinman B, Inzucchi SE et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5:610–621PubMed
122.
Verma S, Mazer CD, Fitchett D et al (2018) Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: sub-analysis of the EMPA-REG OUTCOME® randomized trial. Diabetologia 61:1712–1723PubMedPubMedCentral
123.
Zou CY, Liu XK, Sang YQ et al (2019) Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes. A meta-analysis. Medicine 98(49):e18245PubMedPubMedCentral
124.
Sattar N, McLaren J, Kristensen SL et al (2016) SGLT2 inhibition and cardiovascular events: Why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia 59:1333–1339PubMedPubMedCentral
125.
Ferrannini E, Mark M, Mayoux E et al (2016) CV Protection in the EMPA-REG OUTCOME Trial: A “thrifty substrate” hypothesis. Diabetes Care 39:1108–1114PubMed
126.
127.
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(04):347–357PubMed
128.
Mosenzon O, Wiviott SD, Cahn A et al (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7(08):606–617PubMed
129.
Furtado RHM, Bonaca MP, Raz I (2019) Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation 139(22):2516–2527PubMed
130.
Kato ET, Silverman MG, Mosenzon O et al (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139(22):2528–2536PubMed
131.
McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008PubMed
132.
Neuen BL, Young T, Heerspink HJL (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7:845–854PubMed
133.
VERTIS-CV Investigators, Cannon CP, McGuire DK, Pratley R et al (2018) Design and baseline characteristics of the evaluation of ertugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J 206:11–23
134.
135.
Levin PA, Nguyen H, Wittbrodt ET et al (2017) Glucagon-like peptide‑1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes 10:123–139PubMedPubMedCentral
136.
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322PubMedPubMedCentral
137.
Verma S, Bhatt DL, Bain SC et al (2018) Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease. Circulation 137(20):2179–2183PubMed
138.
Marso SP, Nauck MA, Monk Fries T et al (2018) Myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of liraglutide therapy (from the LEADER trial). Am J Cardiol 121:1467–1470PubMed
139.
Duan CM, Wan TF, Wang Y et al (2019) Cardiovascular outcomes of liraglutide in patients with type 2 diabetes. A systematic review and meta-analysis. Medicine 98(46):e17860PubMedPubMedCentral
140.
Mann JFE, Ørsted DD, Buse JB (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377:839–848PubMed
141.
Kristensen SL, Rørth R, Jhund PS (2019) Cardiovascular, mortality, and kidney outcomes with GLP‑1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7(10):776–785PubMed
142.
Liu J, Li L, Deng K et al (2017) Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 357:j2499PubMedPubMedCentral
143.
Pasternak B, Wintzell V, Eliasson B et al (2020) Use of glucagon like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care 43:1326–1335PubMed
144.
Isaac MRJ (2020) Dulaglutide and Insulin: How can the AWARD studies help guide clinical practice? Diabetes Ther 11:1627–1638
145.
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130PubMed
146.
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomized, placebo-controlled trial. Lancet 394:131–138PubMed
147.
Home PD, Ahrén B, Reusch JEB et al (2017) Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: longterm efficacy with or without rescue therapy. Diabetes Res Clin Pract 131:49–60PubMed
148.
Ahrén B, Carr MC, Murphy K et al (2017) Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Res Clin Pract 126:230–239PubMed
149.
Hernandez AF, Green JB, Janmohamed S et al (2018) Harmony outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. Lancet 392:1519–1529PubMed
150.
Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228–1239PubMed
151.
Fudim M, White J, Pagidipati NJ et al (2019) Effect of Once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure–related outcomes. Insights from the EXSCEL trial. Circulation 140:1613–1622PubMedPubMedCentral
152.
Bonora BM, Avogaro A, Fadini GP (2019) Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 56:1051–1060PubMed
153.
Bethel MA, Patel RA, Merrill P et al (2018) Cardiovascular outcomes with glucagon-like peptide‑1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6:105–113PubMed
154.
Mishriky BM, Cummings DM, Powell JR et al (2019) Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 45:102–109PubMed
155.
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844PubMed
156.
Leiter LA, Bain SC, Hramiak I et al (2019) Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol 18:73PubMedPubMedCentral
157.
PIONEER 6 Investigators, Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 1056:10
158.
Avgerinos I, Michailidis T, Liakos A et al (2020) Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 22:335–345PubMed
159.
Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA 319(15):1580–1591PubMedPubMedCentral
160.
Dicembrini I, Nreu B, Scatena A et al (2017) Microvascular effects of glucagon-like peptide‑1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 54:933–941PubMed
161.
Vilsbøll T, Bain SC, Leiter LA et al (2018) Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 20:889–897PubMedPubMedCentral
162.
Monami M, Nreu B, Scatena A et al (2017) Safety issues with glucagon-like peptide‑1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab 19(09):1233–1241PubMed
163.
Abd El Aziz M, Cahyadi O, Meier JJ et al (2020) Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab 22:699–704PubMed
164.
Azoulay L, Filion KB, Platt RW et al (2016) Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med 176(10):1464–1473PubMed
165.
Wang T, Wang F, Gou Z et al (2015) Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1324515 patients from observational studies. Diabetes Obes Metab 17:32–41PubMed
166.
Cao C, Yang S, Zhou Z (2019) GLP‑1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine 66:157–165PubMed
167.
Russell-Jones D, Pouwer F, Khunti K (2018) Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab 20:488–496PubMed
168.
Marso SP, McGuire DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377(8):723–732PubMedPubMedCentral
169.
Pieber TR, Marso SP, McGuire DK et al (2018) DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 61:58–65PubMed
170.
Lau IT, Lee KF, So WY et al (2017) Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Diabetes Metab Syndr Obes 10:273–284PubMedPubMedCentral
171.
Ritzel R, Roussel R, Giaccari A et al (2018) Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‑year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab 20:541–548PubMed
172.
Bonadonna RC, Renard E, Cheng A et al (2018) Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important? Diabetes Res Clin Pract 142:19–25PubMed
173.
Linnebjerg H, Lam EC, Seger ME et al (2015) Comparison of the pharmacokinetics and pharmacodynamics of LY2963 016 insulin glargine and EU and US-approved versions of lantus insulin glargine in healthy subjects: Three randomized euglycemic clamp studies. Diabetes Care 38:2226–2233PubMed
174.
Rosenstock J, Hollander P, Bhargava A et al (2015) Similar efficacy and safety of LY2963 016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (ELEMENT 2 study). Diabetes Obes Metab 17:734–741PubMed
175.
Yamada T, Kamata R, Ishinohachi K et al (2018) Biosimilar vs originator insulins: systematic review and meta-analysis. Diabetes Obes Metab 20:1787–1792PubMed
176.
But A, De Bruin ML, Bazelier MT et al (2017) Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia 60:1691–1703PubMedPubMedCentral
177.
Maiorino MI, Chiodini P, Bellastella G et al (2017) Insulin and glucagon-like peptide1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care 40:614–624PubMed
178.
Guja C, Frías JP, Somogyi A et al (2018) Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION‑7 randomized study. Diabetes Obes Metab 20:1602–1161PubMedPubMedCentral
179.
Rodbard HW, Lingvay I, Reed J et al (2018) Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab 103(06):2291–2301PubMedPubMedCentral
180.
Gentile S, Fusco A, Colarusso S et al (2018) A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin U‑100 versus concentrated lispro insulin U‑200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence. Expert Opin Drug Saf 17(05):445–450PubMed
181.
Heise T, Hövelmann U, Brøndsted L et al (2015) Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 17:682–688PubMedPubMedCentral
182.
Bowering K, Case C, Harvey J et al (2017) Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: The ONSET 2 trial. Diabetes Care 40(07):951–957PubMed
183.
Leohr J, Dellva MA, Coutant DE et al (2020) Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog(®) (lispro) in patients with type 2 diabetes mellitus: A phase I randomized, crossover study. Clin Pharmacokinet
184.
The SPRINT Research Group (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116PubMedCentral
185.
Düsing R (2017) Therapieziele bei der Hypertoniebehandlung. Dtsch Med Wochenschr 142:1420–1429PubMed
186.
Banegas JR, Ruilope LM, de la Sierra A et al (2018) Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 378:1509–1520PubMed
187.
Khunti K, Gomes MB, Pocock S et al (2018) Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab 20:427–437PubMed
188.
Gough SC, Bode B, Woo V et al (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2(11):885–893PubMed
189.
Diamant M, Nauck MA, Shaginian R et al (2014) Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 37(10):2763–2773PubMed
190.
Ahmann A, Rodbard HW, Rosenstock J et al (2015) Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo controlled trial. Diabetes Obes Metab 17:1056–1064PubMedPubMedCentral
191.
Montvida O, Klein K, Kumar S et al (2017) Addition of or switch to insulin therapy in people treated with glucagon-like peptide‑1 receptor agonists: a real-world study in 66 583 patients. Diabetes Obes Metab 19(01):108–117PubMed
192.
Billings LK, Doshi A, Gouet D et al (2018) Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The DUAL VII randomized clinical trial. Diabetes Care 41(05):1009–1016PubMed
193.
Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(01):111–188PubMed
194.
Parhofer KG, Birkenfeld AL, Krone W et al (2018) Positionspapier zur Lipidtherapie bei Patienten mit Diabetes mellitus. Diabetol Stoffwechs 13(02):S209–S213
Metadaten
Titel
Therapie des Typ-2-Diabetes
verfasst von
Prof. Dr. med. Rüdiger Landgraf
Jens Aberle
Andreas L. Birkenfeld
Baptist Gallwitz
Monika Kellerer
Harald H. Klein
Dirk Müller-Wieland
Michael A. Nauck
Hans-Martin Reuter
Erhard Siegel
Publikationsdatum
17.05.2021
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 4/2021
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-021-00765-5

Weitere Artikel der Ausgabe 4/2021

Die Diabetologie 4/2021 Zur Ausgabe

Mitteilungen des BDI

Mitteilungen des BDI

DDG Praxisempfehlungen

Definition, Klassifikation und Diagnostik des Diabetes mellitus: Update 2020

Leitthema

Mikrobiom – Bedeutung für die Manifestation des Diabetes

Leitthema

Pathomechanismus erhöhte Darmpermeabilität: Was spricht dafür, was dagegen?

Journal Club

Veränderungen des Leberstoffwechsels bei Typ-1- und -2-Diabetes

Leitthema

Mikrobiom und metabolische Fettlebererkrankung (MeFLD)

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft. 

Zu den Praxisempfehlungen
Bildnachweise